Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071014 · ClinicalTrials.gov registry record · Phase 1
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05071014: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05071014 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05071014, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether the combination of pembrolizumab and cryoablation is a safe treatment that causes few or mild side effects in people with mesothelioma. The researchers will also look at whether the combination of pembrolizumab and cryoablation is effective against participants' cancer.
Interventions
- DRUG Pembrolizumab
- PROCEDURE Image-guided cryoablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071014
The ClinicalTrials.gov registry entry for NCT05071014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05071014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05071014 about?
NCT05071014 is a clinical study titled "A Study of Pembrolizumab and Cryoablation in People With Mesothelioma". The researchers are doing this study to find out whether the combination of pembrolizumab and cryoablation is a safe treatment that causes few or mild side effects in people with mesothelioma. The researchers will also look at whether the combination of pembrolizumab and cryoablation is effective ag...
What is the current status of trial NCT05071014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-09-24. Estimated completion is 2023-12-18.
What interventions are being tested in trial NCT05071014?
The interventions under investigation include: Pembrolizumab (DRUG), Image-guided cryoablation (PROCEDURE).
Who is sponsoring clinical trial NCT05071014?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.